Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 350410 | https://doi.org/10.1155/2015/350410

Pornprom Klongkumnuankarn, Kesarin Busaranon, Pithi Chanvorachote, Boonchoo Sritularak, Vichien Jongbunprasert, Kittisak Likhitwitayawuid, "Cytotoxic and Antimigratory Activities of Phenolic Compounds from Dendrobium brymerianum", Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 350410, 9 pages, 2015. https://doi.org/10.1155/2015/350410

Cytotoxic and Antimigratory Activities of Phenolic Compounds from Dendrobium brymerianum

Academic Editor: Maryna Van de Venter
Received16 Oct 2014
Revised18 Dec 2014
Accepted22 Dec 2014
Published15 Jan 2015


Chromatographic separation of a methanol extract prepared from the whole plant of Dendrobium brymerianum led to the isolation of eight phenolic compounds. Among the isolated compounds (18), moscatilin (1), gigantol (3), lusianthridin (4), and dendroflorin (6) showed appreciable cytotoxicity against human lung cancer cell lines with IC50 values of 196.7, 23.4, 65.0, and 125.8 μg/mL, respectively, and exhibited antimigratory property at nontoxic concentrations. This study is the first report on the biological activities of this plant.

1. Introduction

High incidence of cancer metastasis in lung cancer makes this type of cancer among the most severe in the world [1]. Although the patients who receive appropriate treatments have approximately 15-16% of 5-year survival, the relapse of the disease cannot be ignored [2]. Metastasis of cancer cells involves the ability of the cells to migrate away from their origin. The cells migrate and invade through the basement membrane and enter the blood circulation. At their appropriate secondary sites, the cells adhere on the endothelial surface, migrate and invade out of the vessel, and establish themselves to form metastasis [3]. Currently, research on the motility of cancer cells has garnered increased attention, since the discovery of novel antimigratory compounds could lead to new cancer treatments.

Several plants in the genus Dendrobium (Orchidaceae) have long been used in traditional Chinese medicine as tonics [4]. Previous pharmacological studies showed that some Dendrobium species were potential sources of cytotoxic compounds [5]. A number of cytotoxic constituents have been reported from Dendrobium, for example, dengraols A and B from D. gratiosissimum Rchb. f. [6], erianin from D. chrysotoxum Lindl. [7], and moscatilin from several Dendrobium species [8]. The compound moscatilin is of particular interest, as it showed significant antimetastatic activity with relatively low cytotoxicity [9, 10]. Dendrobium brymerianum Rchb. f. is a plant found in Thailand, Burma, Laos, and China [11, 12]. Recently, some phenolic compounds have been identified from this plant [12], but their cytotoxic and antimigratory activities have not been examined. As part of our continuing studies on anticancer agents from Dendrobium plants [13, 14], a MeOH extract obtained from the whole plant of D. brymerianum was evaluated and found to possess significant cytotoxicity against human lung cancer H460 cells, showing 80% inhibition at a concentration of 50 μg/mL. This prompted us to investigate the plant to identify the cytotoxic components, as well as determine their antimigratory activity against cancer cells.

2. Material and Methods

2.1. General

Mass spectra were recorded on a UPLC mass spectrophotometer (Waters 2996-2695, ESI-MS). NMR spectra were recorded on a Bruker Avance DPX-300 FT-NMR spectrometer or a Varian Unity INOVA-500 NMR spectrometer. Optical rotation was measured on a Perkin-Elmer 341 polarimeter. Vacuum-liquid column chromatography (VLC) and column chromatography (CC) were performed on silica gel 60 (Merck, Kieselgel 60, 70–320 mesh), silica gel 60 (Merck, Kieselgel 60, 230–400 mesh), and Sephadex LH-20 (25–100 μm, Pharmacia Fine Chemical Co. Ltd.).

2.2. Plant Material

Sample of D. brymerianum was purchased from Jatujak market, Bangkok, Thailand, in September 2012 and identified by Professor Thatree Phadungcharoen (Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University). A voucher specimen (BS-DB-092555) is deposited at the Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.

2.3. Extraction and Isolation

The dried and powdered whole plant (3 kg) was macerated with MeOH (3 × 10 L) to give a MeOH extract (100 g) after removal of the solvent. This material was fractionated by vacuum-liquid chromatography (VLC) on silica gel (n-hexane-EtOAc gradient) to give 6 fractions (A–F). Fraction F (16.0 g) was separated by column chromatography (CC) over silica gel and eluted with n-hexane-EtOAc gradient, to give 11 fractions (FI–FXI). Fraction FV (2.2 g) was separated on Sephadex LH20 (acetone) to give 8 fractions (FV1–FV8). Compounds 1 (100 mg) and 2 (47 mg) were obtained from fraction FV4 (390 mg) after purification on Sephadex LH 20 (acetone). Fraction FV5 (1.0 g) was further purified on Sephadex LH 20 (acetone) to furnish compound 3 (50 mg). Purification of fraction FV6 (108 mg) on Sephadex LH 20 (acetone) gave compound 4 (5 mg). Fraction FVI (4.8 g) was separated by CC over silica gel (CH2Cl2-EtOAc gradient) to yield 7 fractions (FVI1–FVI7). Fraction FVI4 (1.7 g) was separated on Sephadex LH 20 (acetone) and further purified by CC (silica gel; CH2Cl2-EtOAc, 9 : 1) to afford compounds 5 (6 mg) and 6 (74 mg), respectively. Fraction FVI6 (93 mg) was separated by CC (silica gel; CH2Cl2-EtOAc, gradient) to give compounds 7 (6 mg) and 8 (4 mg), respectively.

Moscatilin (1). Brown amorphous solid; C17H20O5; ESI-MS m/z 305 [M+H]+; 1H NMR (500 MHz, acetone-d6) δ: 2.78 (4H, m, H2-α, H2-α′), 3.75 (6H, s, MeO-3, MeO-5), 3.76 (3H, s, MeO-3′), 6.48 (2H, s, H-2,6), 6.64 (1H, dd, , 2.0 Hz, H-6′), 6.75 (1H, d,  Hz, H-5′), 6.78 (1H, d,  Hz, H-2′); 13C NMR (125 MHz, acetone-d6) δ: 38.3 (C-α′), 38.8 (C-α), 56.1 (MeO-3′), 56.5 (MeO-3, MeO-5), 106.7 (C-2, C-6), 112.9 (C-2′), 115.4 (C-5′), 121.6 (C-6′), 133.1 (C-1), 134.1 (C-1′), 134.8 (C-4), 145.3 (C-4′), 147.9 (C-3′), 148.3 (C-3,5).

Flavanthrinin (2). Brown amorphous solid; C15H12O3; ESI-MS m/z 241 [M+H]+; 1H NMR (500 MHz, acetone-d6) δ: 4.15 (3H, s, MeO-4), 6.98 (1H, d,  Hz, H-3), 7.06 (1H, d,  Hz, H-1), 7.08 (1H, dd, , 2.5 Hz, H-6), 7.40 (1H, d,  Hz, H-8), 7.42 (1H, d,  Hz, H-5), 7.49 (1H, d,  Hz, H-10), 7.62 (1H, d,  Hz, H-9); 13C NMR (125 MHz, acetone-d6) δ: 58.5 (MeO-4), 102.5 (C-3), 107.7 (C-1), 114.0 (C-4a), 116.9 (C-6), 119.9 (C-4b), 121.0 (C-8), 126.9 (C-10), 127.4 (C-5), 129.7 (C-9), 134.9 (C-8a), 137.0 (C-10a), 155.2 (C-7), 156.3 (C-2), 157.3 (C-4).

Gigantol (3). Brown amorphous solid; C16H18O4; ESI-MS m/z 275 [M+H]+; 1H NMR (500 MHz, acetone-d6) δ: 2.78 (4H, m, H2-α, H2-α′), 3.69 (3H, s, MeO-3′), 3.78 (3H, s, MeO-3), 6.22 (1H, t,  Hz, H-2), 6.28 (1H, t,  Hz, H-4), 6.30 (1H, t,  Hz, H-6), 6.64 (1H, dd, , 1.5 Hz, H-6′), 6.69 (1H, d,  Hz, H-5′), 6.79 (1H, d,  Hz, H-2′); 13C NMR (125 MHz, acetone-d6) δ: 37.9 (C-α′), 39.0 (C-α), 55.2 (MeO-3), 56.0 (MeO-3′), 99.6 (C-4), 106.2 (C-6), 108.8 (C-2), 112.8 (C-5′), 115.4 (C-2′), 121.5 (C-6′), 134.0 (C-1′), 145.1 (C-4′), 145.4 (C-1), 147.9 (C-3′), 159.1 (C-3), 161.7 (C-5).

Lusianthridin (4). Brown amorphous solid; C15H14O3; ESI-MS m/z 243 [M+H]+; 1H NMR (500 MHz, acetone-d6) δ: 3.72 (3H, s, MeO-2), 6.36 (1H, d,  Hz, H-1), 6.42 (1H, d,  Hz, H-3), 6.67 (1H, dd, , 2.5 Hz, H-6), 6.70 (1H, d,  Hz, H-8), 8.22 (1H, d,  Hz, H-5); 13C NMR (125 MHz, acetone-d6) δ: 30.6 (C-9), 31.4 (C-10), 55.2 (MeO-2), 101.5 (C-3), 105.8 (C-1), 113.4 (C-6), 114.9 (C-8), 115.7 (C-4a), 125.8 (C-4b), 129.8 (C-5), 139.7 (C-8a), 141.3 (C-10a), 155.8 (C-4), 155.9 (C-7), 159.2 (C-2).

Nobilone (5). Red amorphous solid; C14H10O4; ESI-MS m/z 243 [M+H]+; 1H NMR (500 MHz, acetone-d6) δ: 4.13 (3H, s, MeO-4), 6.78 (1H, d,  Hz, H-3), 6.80 (1H, d,  Hz, H-1), 6.93 (1H, dd, , 1.5 Hz, H-6), 7.10 (1H, d,  Hz, H-8), 7.13 (1H, d,  Hz, H-5); 13C NMR (125 MHz, acetone-d6) δ: 57.5 (MeO-4), 105.9 (C-1), 106.2 (C-3), 116.7 (C-8), 122.6 (C-4a), 125.0 (C-6), 128.0 (C-4b), 130.2 (C-5), 135.8 (C-8a), 137.2 (C-9a), 151.6 (C-7), 153.5 (C-4), 160.9 (C-2), 193.2 (C-9).

Dendroflorin (6). Red amorphous solid; C14H10O5; ESI-MS m/z 259 [M+H]+; 1H NMR (500 MHz, acetone-d6) δ: 4.10 (3H, s, MeO-4), 6.58 (1H, d,  Hz, H-7), 6.76 (1H, d,  Hz, H-3), 6.79 (1H, d,  Hz, H-1), 6.87 (1H, d,  Hz, H-6); 13C NMR (125 MHz, acetone-d6) δ: 57.4 (MeO-4), 105.6 (C-1), 106.1 (C-3), 117.4 (C-8a), 119.7 (C-7), 122.4 (C-4a), 124.3 (C-4b), 128.9 (C-6), 137.4 (C-9a), 145.1 (C-5), 152.8 (C-8), 154.1 (C-4), 160.9 (C-2), 195.3 (C-9).

Denchrysan B (7). Red amorphous solid; C14H12O4; ESI-MS m/z 245 [M+H]+;   −7.9 (, MeOH); 1H NMR (300 MHz, acetone-d6) δ: 4.06 (3H, s, MeO-4), 5.37 (1H, br s, H-9), 6.59 (1H, br s, H-3), 6.73 (1H, dd, , 1.5 Hz, H-6), 6.83 (1H, br s, H-1), 7.03 (1H, m, H-8), 7.07 (1H, m, H-7); 13C NMR (75 MHz, acetone-d6) δ: 57.0 (MeO-4), 75.4 (C-9), 100.3 (C-3), 107.2 (C-1), 116.9 (C-6), 117.0 (C-8), 118.9 (C-4a), 124.7 (C-4b), 128.4 (C-7), 148.5 (C-8a), 150.8 (C-9a), 151.4 (C-5), 153.0 (C-4), 159.6 (C-2).

Tristin (8). Brown amorphous solid; C15H16O4; ESI-MS m/z 261 [M+H]+; 1H NMR (300 MHz, acetone-d6) δ: 2.74 (4H, m, H2-α, H2-α′), 3.78 (3H, s, MeO-3′), 6.17 (1H, d,  Hz, H-4), 6.20 (2H, d,  Hz, H-2, H-6), 6.63 (1H, dd, , 1.5 Hz, H-6′), 6.69 (1H, d,  Hz, H-5′), 6.79 (1H, d,  Hz, H-2′); 13C NMR (75 MHz, acetone-d6) δ: 37.9 (C-α′), 38.9 (C-α), 56.1 (MeO-3′), 101.0 (C-4), 107.8 (C-2, C-6), 112.8 (C-2′), 115.5 (C-5′), 121.5 (C-6′), 134.1 (C-1′), 145.1 (C-4′), 145.5 (C-1), 148.0 (C-3′), 159.2 (C-3, C-5).

2.4. Cells and Reagents

Lung cancer H460 cells were obtained from the American Type Culture Collection (Manassas, VA). Cells were cultured in RPMI 1640 containing 5% fetal bovine serum, 2 mM L-glutamine, and 100 units/mL penicillin/streptomycin in a 5% CO2 environment at 37°C. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and other chemicals were obtained from Sigma Chemical, Inc. (St. Louis, MO).

2.5. Cell Viability Assay

To determine cytotoxicity, cell viability was determined by modified MTT assay [15] which measured cellular capacity to reduce MTT (yellow) to purple formazan crystal by mitochondrial dehydrogenase. The cells were seeded at a density of 1 × 104 cells/well in a 96-well plate and allowed to attach for 12 h, treated with different concentrations of compounds in DMSO (with the final concentration of DMSO less than 0.1% in each well) for 24 h, and then incubated with 100 μL of 500 μg/mL MTT solution for 4 h at 37°C. Then, MTT solution was removed, and 100 μL of 99.9% DMSO was added to dissolve the formazan crystal. The intensity of formazan product was measured at 570 nm using a microplate reader. All analyses were performed in at least three independent replicate cultures. The cell viability was calculated as follows:

2.6. Assay for Antimigratory Activity

Migratory activity of the cancer cells was evaluated by wound-healing assay [16]. Briefly, a monolayer of cells at a density of 1.5 × 104 cells/well was cultured in 96-well plates, and a wound space was created by a 1 mm width tip. After rinsing with PBS, the cell monolayers were treated with nontoxic concentration of compounds (0.1 μg/mL) and allowed to migrate for 0–48 h. Micrographs were taken under a phase-contrast microscope (×100; Olympus IX51 with DP70), and wound spaces were measured from 10 random fields of view using Olympus DP Controller software. Quantitative analysis of cell migration was performed by using an average wound space from random fields of view, and the relative migration was calculated.

2.7. Data/Statistical Analysis

All results from three or more independent experiments were expressed as means ± SD. Statistical differences between means were determined using the analysis of variance (ANOVA) and the post hoc test. A value of less than 0.05 () was considered statistically significant. The IC50 value was obtained using the GraphPad Prism software.

2.8. Determination of Total Phenolic Content

The total phenolic content (TPC) was determined by Folin-Ciocalteu method [17]. Assays were conducted in a 96-well microtiter plate. Briefly, 20 μL of the plant extract solution (0.5 mg/mL in ethanol) was added to 1 : 10 diluted Folin-Ciocalteu reagent (100 μL). After 5 minutes, 100 μL of Na2CO3 (75 g/100 mL in deionized water) was added. After incubation at room temperature for 1 hr, the absorbance was measured at 765 nm using a Perkin-Elmer Victor3 1420 multilabel counter. Gallic acid (Sigma) was used as a reference standard, and the total phenolic content was expressed as mg of gallic acid equivalent (GAE)/g dried plant material.

3. Results and Discussion

The total phenolic content of the dried plant material was found to be 1.13 mg GAE/g, which was in the same level as that of Dendrobium nobile [18]. Chromatographic separation of this MeOH extract resulted in the isolation of eight phenolic compounds which included moscatilin (1) [19], flavanthrinin (2) [20], gigantol (3) [21], lusianthridin (4) [22], nobilone (5) [23], dendroflorin (6) [24], denchrysan B (7) [25], and tristin (8) [21]. The structures of these isolates (Figure 1) were determined through analysis of their 1H NMR, 13C NMR, and MS data in comparison with previously reported values. Compounds 1, 2, 4, 5, 7, and 8 were not found in the previous study [12].

Compounds 18 were evaluated for cytotoxicity against human lung cancer H460 cells using established protocols [15], and the results are summarized in Table 1. It can be seen that, apart from moscatilin (1) which has been earlier reported for cytotoxic and antimigratory effects [9], only gigantol (3), lusianthridin (4), and dendroflorin (6) exhibited appreciable cytotoxic properties, whereas the others were inactive (IC50 > 200 μg/mL). From these preliminary limited data it could be speculated that the stronger cytotoxicity of the extract, as compared with the individual components, was probably due to the additive or synergistic effects from the eight phenolic (18) and/or other unisolated compounds. Compounds 3, 4, and 6 were further investigated for antimigratory potential in comparison with 1, using a modified method of the wound-healing assay [16]. In a previous report, moscatilin (1) showed inhibition against the migration of breast MDA-MB-231 cells [10] and thus could serve as a positive control in this study. In the present examination, each compound was evaluated for antimigratory activity at a noncytotoxic concentration (0.1 μg/mL) to avoid the possible interfering cytotoxic effect. The human lung cancer H460 cells were then allowed to migrate in the presence or absence of the test compound for 0, 6, 12, 24, and 48 h, after which the migratory activity was measured. The results, as shown in Figures 2, 3, 4, and 5, indicated that each of the tested compounds exhibited significant antimigratory activity in comparison with the untreated control. As summarized in Figure 6, all of the compounds (1, 3, 4, and 6) inhibited the migration of the cells across the wound space in a time-dependent manner. During the first 24 h, dendroflorin (6) appeared to be the strongest antimigratory compound; however, after 48 h, moscatilin (1) became the most potent compound, as a result of the substantial increase of its activity during the period of 24–48 h. It should be mentioned that the antimigratory effects of moscatilin (1) and gigantol (3) have been earlier demonstrated in other cancer cells, for example, human lung H23 and breast MDA-MB-231 cells [9, 10, 26]. Additionally, gigantol (3) has been shown to suppress lung cancer cell migration through a caveolin-1-dependent pathway [26]. It is worth noting that, among the compounds tested in this study, gigantol (3) was the weakest antimigratory agent despite its strong cytotoxicity, suggesting that no linear correlation exists between cytotoxicity and antimigratory activity.

CompoundsIC50 (μg/mL)

Moscatilin (1)196.7 ± 2.62
Flavanthrinin (2)>200
Gigantol (3)23.4 ± 3.99
Lusianthridin (4)65.0 ± 3.51
Nobilone (5)>200
Dendroflorin (6)125.8 ± 3.29
Denchrysan B (7)>200
Tristin (8)>200

It is known that cell migration may be regulated by the caveolin-1 and/or the protein kinase B (Akt) signaling pathway [27]. In certain cases, particularly in lung cancer migration, overexpression of caveolin-1 is believed to play the predominant role [16]. The apparent high level of caveolin-1 expression in H460 cells in this study (data not shown) might suggest the involvement of caveolin-1 in the cancer cell migration, although more detailed studies are needed before any conclusion can be drawn.

4. Conclusion

In summary, in this communication we provide new information on the cytotoxic and antimigratory effects of the phenolic compounds isolated from Dendrobium brymerianum. To the best of our knowledge, this is the first report on the biological activities of this plant. Our findings on the antimigratory activities of moscatilin (1) and gigantol (3) are in agreement with earlier reports. In addition, our preliminary data revealed for the first time the antimigratory potential of lusianthridin (4) and dendroflorin (6). The biological data obtained in the present study should be useful for the future development of new antimetastatic drugs.

Conflict of Interests

The authors declare no conflict of interests.


This work was supported by a research grant from Ratchadaphiseksomphot Endowment Fund (CU-57-003-HR) of Chulalongkorn University. Pornprom Klongkumnuankarn is grateful to the Graduate School of Chulalongkorn University for a research grant. The authors thank Professor Thatree Phadungcharoen (Chulalongkorn University) for the plant identification. Thanks are also due to The Research Instrument Center of Faculty of Pharmaceutical Sciences, Chulalongkorn University, for providing research facilities.

Supplementary Materials

Lyon/Geneva, 12 December 2013 – The International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization, today released the latest data on cancer incidence, mortality, and prevalence worldwide.1 The new version of IARC’s online database, GLOBOCAN 2012, provides the most recent estimates for 28 types of cancer in 184 countries worldwide and offers a comprehensive overview of the global cancer burden.

GLOBOCAN 2012 reveals striking patterns of cancer in women and highlights that priority should be given to cancer prevention and control measures for breast and cervical cancers globally.

Global burden rises to 14.1 million new cases and 8.2 million cancer deaths in 2012

According to GLOBOCAN 2012, an estimated 14.1 million new cancer cases and 8.2 million cancer-related deaths occurred in 2012, compared with 12.7 million and 7.6 million, respectively, in 2008. Prevalence estimates for 2012 show that there were 32.6 million people (over the age of 15 years) alive who had had a cancer diagnosed in the previous five years.

The most commonly diagnosed cancers worldwide were those of the lung (1.8 million, 13.0% of the total), breast (1.7 million, 11.9%), and colorectum (1.4 million, 9.7%). The most common causes of cancer death were cancers of the lung (1.6 million, 19.4% of the total), liver (0.8 million, 9.1%), and stomach (0.7 million, 8.8%).

Projections based on the GLOBOCAN 2012 estimates predict a substantive increase to 19.3 million new cancer cases per year by 2025, due to growth and ageing of the global population. More than half of all cancers (56.8%) and cancer deaths (64.9%) in 2012 occurred in less developed regions of the world, and these proportions will increase further by 2025.

  1. Supplementary Material


  1. WHO, “International Agency for Research on Cancer,” World Cancer Report, 2013. View at: Google Scholar
  2. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA: Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at: Publisher Site | Google Scholar
  3. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at: Publisher Site | Google Scholar
  4. J. Hu, W. Fan, F. Dong, Z. Miao, and J. Zhou, “Chemical components of Dendrobium chrysotoxum,” Chinese Journal of Chemistry, vol. 30, no. 6, pp. 1327–1330, 2012. View at: Publisher Site | Google Scholar
  5. T. B. Ng, J. Liu, J. H. Wong et al., “Review of research on Dendrobium, a prized folk medicine,” Applied Microbiology and Biotechnology, vol. 93, no. 5, pp. 1795–1803, 2012. View at: Publisher Site | Google Scholar
  6. C.-F. Zhang, M. Wang, L. Wang et al., “Chemical constituents of Dendrobium gratiosissimum and their cytotoxic activities,” Indian Journal of Chemistry, vol. 47, no. 6, pp. 952–956, 2008. View at: Google Scholar
  7. Y. M. Li, H. Y. Wang, and G. Q. Liu, “Erianin induces apoptosis in human leukemia HL-60 cells,” Acta Pharmacologica Sinica, vol. 22, pp. 1018–1022, 2001. View at: Google Scholar
  8. C.-K. Ho and C.-C. Chen, “Moscatilin from the orchid Dendrobrium loddigesii is a potential anticancer agent,” Cancer Investigation, vol. 21, no. 5, pp. 729–736, 2003. View at: Publisher Site | Google Scholar
  9. A. Kowitdamrong, P. Chanvorachote, B. Sritularak, and V. Pongrakhananon, “Moscatilin inhibits lung cancer cell motility and invasion via suppression of endogenous reactive oxygen species,” BioMed Research International, vol. 2013, Article ID 765894, 11 pages, 2013. View at: Publisher Site | Google Scholar
  10. H.-C. Pai, L.-H. Chang, C.-Y. Peng et al., “Moscatilin inhibits migration and metastasis of human breast cancer MDA-MB-231 cells through inhibition of Akt and Twist signaling pathway,” Journal of Molecular Medicine, vol. 91, no. 3, pp. 347–356, 2013. View at: Publisher Site | Google Scholar
  11. G. Seidenfaden, “Orchid genera in Thailand XII. Dendrobium Sw,” Opera Botanica, vol. 83, pp. 1–295, 1985. View at: Google Scholar
  12. Y.-G. Chen, H. Yu, and Y. Liu, “Chemical constituents from Dendrobium brymerianum Rchb. f,” Biochemical Systematics and Ecology, vol. 57, pp. 175–177, 2014. View at: Publisher Site | Google Scholar
  13. T. Phechrmeekha, B. Sritularak, and K. Likhitwitayawuid, “New phenolic compounds from Dendrobium capillipes and Dendrobium secundum,” Journal of Asian Natural Products Research, vol. 14, no. 8, pp. 748–754, 2012. View at: Publisher Site | Google Scholar
  14. P. Chanvorachote, A. Kowitdamrong, T. Ruanghirun, B. Sritularak, C. Mungmee, and K. Likhitwitayawuid, “Anti-metastatic activities of bibenzyls from Dendrobium pulchellum,” Natural Product Communications, vol. 8, no. 1, pp. 115–118, 2013. View at: Google Scholar
  15. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at: Publisher Site | Google Scholar
  16. S. Luanpitpong, S. J. Talbott, Y. Rojanasakul et al., “Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1,” The Journal of Biological Chemistry, vol. 285, no. 50, pp. 38832–38840, 2010. View at: Publisher Site | Google Scholar
  17. G. Miliauskas, P. R. Venskutonis, and T. A. van Beek, “Screening of radical scavenging activity of some medicinal and aromatic plant extracts,” Food Chemistry, vol. 85, no. 2, pp. 231–237, 2004. View at: Publisher Site | Google Scholar
  18. H.-B. Li, Y. Jiang, C.-C. Wong, K.-W. Cheng, and F. Chen, “Evaluation of two methods for the extraction of antioxidants from medicinal plants,” Analytical and Bioanalytical Chemistry, vol. 388, no. 2, pp. 483–488, 2007. View at: Publisher Site | Google Scholar
  19. P. L. Majumder and R. C. Sen, “Moscatilin, a bibenzyl derivative from the orchid Dendrobium moscatum,” Phytochemistry, vol. 26, no. 7, pp. 2121–2124, 1987. View at: Publisher Site | Google Scholar
  20. X. Zhang, J. K. Xu, N. L. Wang, H. Kurihara, and X. S. Yao, “Antioxidant phenanthrenes and lignans from Dendrobium nobile,” Journal of Chinese Pharmaceutical Sciences, vol. 17, pp. 314–318, 2008. View at: Google Scholar
  21. Y. Chen, J. Xu, H. Yu et al., “Cytotoxic phenolics from Bulbophyllum odoratissimum,” Food Chemistry, vol. 107, no. 1, pp. 169–173, 2008. View at: Publisher Site | Google Scholar
  22. X.-Y. Guo, J. Wang, N.-L. Wang, S. Kitanaka, and X.-S. Yao, “9, 10-Dihydrophenanthrene derivatives from Pholidota yunnanensis and scavenging activity on DPPH free radical,” Journal of Asian Natural Products Research, vol. 9, no. 2, pp. 165–174, 2007. View at: Publisher Site | Google Scholar
  23. X. Zhang, J. K. Xu, J. Wang et al., “Bioactive bibenzyl derivatives and fluorenones from Dendrobium nobile,” Journal of Natural Products, vol. 70, no. 1, pp. 24–28, 2007. View at: Publisher Site | Google Scholar
  24. C. Fan, W. Wang, Y. Wang, G. Qin, and W. Zhao, “Chemical constituents from Dendrobium densiflorum,” Phytochemistry, vol. 57, no. 8, pp. 1255–1258, 2001. View at: Publisher Site | Google Scholar
  25. Q.-H. Ye, W.-M. Zhao, and G.-W. Qin, “New fluorenone and phenanthrene derivatives from Dendrobium chrysanthum,” Natural Product Research, vol. 17, no. 3, pp. 201–205, 2003. View at: Publisher Site | Google Scholar
  26. S. Charoenrungruang, P. Chanvorachote, B. Sritularak, and V. Pongrakhananon, “Gigantol, a bibenzyl from Dendrobium draconis, inhibits the migratory behavior of non-small cell lung cancer cells,” Journal of Natural Products, vol. 77, no. 6, pp. 1359–1366, 2014. View at: Publisher Site | Google Scholar
  27. D. P. Brazil and B. A. Hemmings, “Ten years of protein kinase B signalling: a hard Akt to follow,” Trends in Biochemical Sciences, vol. 26, no. 11, pp. 657–664, 2001. View at: Publisher Site | Google Scholar

Copyright © 2015 Pornprom Klongkumnuankarn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1694 Views | 1189 Downloads | 18 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.